Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication

Antiviral Research

Volumn 53, Issue 1, 2002, Pages 35-45

  Bisset, Leslie R ^a   Lutz, Hans ^a   BÖni, Jürg ^a   Hofmann Lehmann, Regina ^a   Lüthy, Ruedi ^b   Schüpbach, Jörg ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b KLINIK IM PARK   (Switzerland)

Author keywords

Abacavir; Antiretroviral; FIV; Hydroxyurea; In vitro; Lamivudine; Zidovudine

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ENZYME INHIBITOR; HYDROXYUREA; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; ZIDOVUDINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEASIBILITY STUDY; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CATS; CELL LINE; DIDEOXYNUCLEOSIDES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMANS; HYDROXYUREA; IMMUNODEFICIENCY VIRUS, FELINE; KIDNEY; LAMIVUDINE; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION; ZIDOVUDINE;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0036027833     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00190-5     Document Type: Article

References (43)

1. Preliminary analysis of the Concorde trial
2. Quantification of in vitro retroviral replication using a one-tube real-time RT-PCR system incorporating direct RNA preparation
3. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
4. 159U89, a novel carbocylic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
5. An overview of the clinical experience with hydroxyurea
6. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine
7. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
8. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
9. HAART stopping news: Experts examine structured therapy interruption for HIV
10. 1998 Revision to the British HIV Association Guidelines for antiretroviral treatment of HIV seropositive individuals
11. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms
12. Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus
13. Toward a universal inhibitor of retroviral proteases: Comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV
14. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
15. Structural studies of FIV and HIV-1 proteases complexed with all efficient inhibitor of FIV protease
16. Hydroxyurea and HIV: 5 Years later - From antiviral to immune-modulating effects
17. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
18. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters
19. Comparative pharmokinetics of antiviral nucleoside analogues
20. Rapid colorometric assay for cellular growth and survival: Application to proliferation and cytotoxicity assay
21. Protease inhibitor-sparing HAART: A review of key studies
22. Testing anti-HIV drugs in the FIV model
23. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome
24. Direct comparisons of inhibitor sensitivities of reverse transcriptases from feline and human immunodeficiency viruses
25. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: A randomized trial of double versus triple therapy. Swiss HIV Cohort Study
26. Increased activation of the combination 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea
27. How immune-based interventions can change HIV therapy
28. Identification of the Rev transactivation and Rev-reponsive elements of feline immunodeficiency virus
29. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy
30. Mutants of feline immunodeficiency virus resistant to 3′-azido-3′-deoxythymidine
31. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection
32. Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection
33. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis
34. A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-β-2′,3′-dideoxy-3′-thiacytidine and 3′-azido-3′-deoxythymidine
35. Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents
36. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects
37. Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-inducing cytopathic effect: Development of a new method for screening of anti-FIV substances in vitro
38. (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection
39. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection
40. FIV infection of the domestic cat: An animal model for AIDS
41. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus
42. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia. The Swiss HIV Cohort Study